Lamos, Cristina; Hunger, Robert (2020). [Checkpoint inhibitors-indications and application in melanoma patients]. Zeitschrift für Rheumatologie, 79(8), pp. 818-825. Springer-Medizin-Verlag 10.1007/s00393-020-00870-8
|
Text
393_2020_Article_870.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (450kB) | Preview |
Since its introduction in 2011 the checkpoint inhibitor ipilimumab, has revolutionized the whole of oncology. After this first major step more checkpoint inhibitors, such as the PD‑1 antibodies nivolumab and pembrolizumab have been developed. The results are groundbreaking, especially in advanced malignant melanoma, which only a few years ago led to certain death in most cases after only a few months. Currently, the application of checkpoint inhibitors has been extended to many more tumor entities, with very promising results.
Item Type: |
Journal Article (Further Contribution) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology |
UniBE Contributor: |
Lamos, Cristina, Hunger, Robert |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0340-1855 |
Publisher: |
Springer-Medizin-Verlag |
Language: |
German |
Submitter: |
Andrea Studer-Gauch |
Date Deposited: |
14 Dec 2020 16:12 |
Last Modified: |
05 Dec 2022 15:42 |
Publisher DOI: |
10.1007/s00393-020-00870-8 |
PubMed ID: |
32926216 |
Uncontrolled Keywords: |
CTLA-4 blocker Immuno-oncology Melanoma therapy PD-1 inhibitor System therapy |
BORIS DOI: |
10.7892/boris.148357 |
URI: |
https://boris.unibe.ch/id/eprint/148357 |
Actions (login required)
 |
Edit item |